Leukemia patients who failed stopping meds may get another shot at drug-free remission

This study tests whether adding asciminib to standard tyrosine kinase inhibitors (TKIs) can help people with chronic myeloid leukemia (CML) safely stop all medication and remain in remission. It includes 69 adults who have been on TKIs for at least 5 years but previously failed to stay in remission after stopping treatment. Participants will take asciminib plus their current TKI, then attempt to stop both and be monitored for one year.